title: Salvage therapy with lenalidomide containing regimen for relapsed/refractory Castleman disease: a report of three cases.
abstract: Castleman disease (CD) is uncommon non-clonal lymphoproliferative disorder with unknown etiology. No standard therapy is recommended for relapsed/refractory CD patients, thus requiring development of novel experimental approaches. Our cohort of three adult patients with multicentric CD (MCD) were treated with refractory to traditional chemotherapy lenalidomide-containing regimens (10-25 mg lenalidomide perorally administered on days 1-21 in 28-day cycle) as second- to fourth-line treatment. Partial remission was achieved in first plasma-cell CD patient, who relapsed seven months after autologous hematopoietic stem cell transplantation and then failed to respond to four cycles of chemotherapy. Partial remission was obtained in second patient with CD and polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome. Third case showed complete remission with complete disappearance of pleural effusion and ascites and normalization of platelet count. To conclude, encouraging clinical responses were achieved in cohort of three patients with lenalidomide-based regimen, though long-term efficacy remains to be observed.We propose further investigation of therapeutic potential of this drug in treating MCD.
authors.affiliation: Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China.
authors.forename: Xinping
authors.initials: X
authors.lastname: Zhou
authors.affiliation: Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China.
authors.forename: Juying
authors.initials: J
authors.lastname: Wei
authors.affiliation: Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China.
authors.forename: Yinjun
authors.initials: Y
authors.lastname: Lou
authors.affiliation: Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China.
authors.forename: Gaixiang
authors.initials: G
authors.lastname: Xu
authors.affiliation: Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China.
authors.forename: Min
authors.initials: M
authors.lastname: Yang
authors.affiliation: Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Liu
authors.affiliation: Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China.
authors.forename: Liping
authors.initials: L
authors.lastname: Mao
authors.affiliation: Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China.
authors.forename: Hongyan
authors.initials: H
authors.lastname: Tong
authors.affiliation: Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China. jiej0503@163.com.
authors.forename: Jie
authors.initials: J
authors.lastname: Jin
mesh_terms: D000328:Adult; D005871:Castleman Disease / Q000473:pathology* / Q000628:therapy*; D003131:Combined Modality Therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000077269:Lenalidomide; D008198:Lymph Nodes / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D016879:Salvage Therapy; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives*; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D013792:Thalidomide; D000077269:Lenalidomide
keywords: Castleman disease; lenalidomide